Skip to content

Research at St Andrews

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

Research output: Contribution to journalArticle

  1. 2005
  2. REMoxTB Consortium (External organisation)

    Stephen Henry Gillespie (Chair)
    1 Aug 2005 → …

    Activity: Membership typesMembership of research network

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

    Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., Minja, L. T., Hunt, R. D., Charalambous, S., Hanekom, M., Semvua, H. H., Mpagama, S. G., Manyama, C., Mtafya, B., Reither, K., Wallis, R. S. & 9 others, Venter, A., Narunsky, K., Mekota, A., Henne, S., Colbers, A., Plemper van Balen, G., Gillespie, S. H., Phillips, P. P. J. & Hoelscher, M., Jan 2017, In : Lancet Infectious Diseases. 17, 1, p. 39-49 11 p.

    Research output: Contribution to journalArticle

  2. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

    Aliberti, S., Reyes, L. F., Faverio, P., Sotgiu, G., Dore, S., Rodriguez, A. H., Soni, N. J., Restrepo, M. I., GLIMP investigators & Dhasmana, D. J., Dec 2016, In : Lancet Infectious Diseases. 16, 12, p. 1364-1376 13 p.

    Research output: Contribution to journalArticle

  3. Chasing Koch's chimera

    Klatser, P., Anthony, R., Barry, C., Drobniewski, F., Hoffner, S., Niemann, S. & Gillespie, S., 1 Jan 2013, In : The Lancet Infectious Diseases. 13, 4, p. 289-291 3 p.

    Research output: Contribution to journalLetter

  4. Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study

    Harris, S. R., Cartwright, E. J. P., Toeroek, M. E., Holden, M. T. G., Brown, N. M., Ogilvy-Stuart, A. L., Ellington, M. J., Quail, M. A., Bentley, S. D., Parkhill, J. & Peacock, S. J., Feb 2013, In : Lancet Infectious Diseases. 13, 2, p. 130-136 7 p.

    Research output: Contribution to journalArticle

ID: 147224141

Top